Please login to the form below

Not currently logged in
Email:
Password:

emotive partners with Rare Disease UK for public awareness campaign

Will launch the campaign ahead of next month's Rare Disease Day

Rare Disease Day

Healthcare communications agency emotive has teamed up with Rare Disease UK to develop a public awareness campaign, which will be launched ahead of Rare Disease Day on 28 February.

The Campaign, which will highlight the large and often hidden scale and impact of rare diseases, aims to ‘energise’ the public to discover more about rare diseases.

According to Rare Disease UK, which is run by charity group Genetic Alliance UK, more than 7% of the UK population is affected by a rare disease at some point in their lives, but despite this public awareness is reported low.

Jayne Spink, chair of Rare Disease UK, said: “We need to change this if we are to reduce feelings of isolation, and increase understanding of the common issues faced by patients and carers.

“Better awareness can also help to increase access to support services and treatment, and secure funding and engagement in research.”

Since 2009, the group has been working with health departments across the UK to implement the UK strategy for Rare Diseases to ensure patients living with rare conditions have access to services, treatment and support.

Partnering with emotive, Rare Disease UK hopes that the agency can bring creativity to their campaign.

Chris Edmonds, managing director at emotive, said: “We were privileged to work with Rare Disease UK at our offsite annual conference in the summer where we helped them map out a communication strategy for 2018 and beyond.

“The team at emotive have worked extremely hard and used our deep knowledge of rare diseases to come up with a great creative concept and we’re excited to see it go live later in February.”

Article by
Gemma Jones

26th January 2018

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Waiting room
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs...

Infographics